Empagliflozin for metabolic changes linked to olanzapine in schizophrenia
About this title
Read the official source — NCT05669742This study evaluates the safety and effectiveness of Empagliflozin for people with schizophrenia.
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Empagliflozin for people with schizophrenia.
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- TantaSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 40
- Sponsor
- Tanta University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Egypt
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05669742
- Official title
Show the full official title
Evaluating the Safety and Efficacy of Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients.A Double-Blind, Randomized, Placebo-Controlled Trial
Recruitment & locations
Tanta
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Empagliflozin for people with schizophrenia.
Who is behind this study?
The study sponsor is Tanta University, a university.
Does this study involve medication?
Yes. The study involves medication, including Empagliflozin and olanzapine.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
